



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 18 December 2019

Re: Freedom of Information Request
Ref: 341 - 2019

Thank you for your email dated the 25th November 2019, requesting number of Oncology patients treated by your Trust with the stated therapies, during the time period January 2019 to June 2019.

The information that you require is as follows:

We are conducting a piece of research into oncology treatments. Under the Freedom of Information Act 2000 we would like to request the information contained in the attached document.

Please see Appendix 1

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be

addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre
NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you
have the right to apply directly to the Information Commissioner for a decision.
The Information Commissioner can be contacted at: Information Commissioner's
Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Appendix 1

FOI Request re Number of Patients Treated

Please detail the number of Oncology¹ patients treated² by your Trust with the stated therapies, during the time period **January 2019 to June 2019** inclusive.

Please note, in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown in our response below.

Points of Interest:

- We only record staging at presentation to The Clatterbridge Cancer Centre (CCC), we are therefore unable to ascertain whether patients were metastatic when treated.
- CCC have provided 'single' agent drugs only (not combination drugs).
- Patients may have had more than one drug
- Total number of patients treated – this figure includes patients treated with the below regimes from different tumour sites (e.g. Breast, Prostate, Vulva etc...)
- Individual patients treated per regime (not at cycle level)

	Total Number of Patients Treated:				
	Total Number of Patients Treated	Head & Neck Cancer	Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	40	0	82	180	Exempt under S.40
Nivolumab (Opdivo)	12	21	43	10	35
Ipilimumab (Yervoy)	0	0	Exempt under S.40	0	0
Dabrafenib (Tafinlar)	0	0	Exempt under S.40	0	0
Cabozantinib (Cabometyx)	Exempt under S.40	Exempt under S.40	0	0	30
Sunitinib (Sutent)	Exempt under S.40	0	0	0	13
Pazopanib (Votrient)	Exempt under S.40	0	0	0	11

1

Cancer Type	Diagnoses Codes (ICD10)
Head & Neck	C00-C14; C30-C32
Adjuvant Melanoma	C43 (treatment as additional treatment following primary)
Metastatic Melanoma	C43 plus C77, C78, C79
NSCLC	C34
RCC	C64

² Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).

Axitinib (Inlyta)	Exempt under S.40	0	0	0	Exempt under S.40
Atezolizumab (Tecentriq)	18	Exempt under S.40	0	35	0
Sorafenib (Nexavar)	18	Exempt under S.40	0	0	0
Tivozanib (Fotivda)	Exempt under S.40	0	0	0	26
Lenvatinib (Lenvima)	9	Exempt under S.40	0	0	Exempt under S.40
Cetuximab (Erbix)	78	Exempt under S.40	0	0	0
Everolimus (Afinitor)	28	0	0	Exempt under S.40	Exempt under S.40
Vemurafenib (Zelboraf)	0	0	0	0	0